This is the classic website, which will be retired eventually. Please visit the modernized instead.

Key Record Dates Identifier: NCT05338775
Brief Title: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)

First Submitted : March 31, 2022
First Submitted that Met QC Criteria : April 20, 2022
First Posted : April 21, 2022

Last Update Submitted that Met QC Criteria : March 26, 2024
Last Update Posted : March 27, 2024